BioWorld

Jan. 9, 2004

Opportunistic Axonyx Raises $50M Through Public Market

Months after raising $25 million in a private placement, Axonyx Inc. is at it again. But this time, Axonyx has set its sights higher, looking to bring in $50 million. (BioWorld Today) Read More

Novacea Series C Gets $35M To Push Cancer Compounds

Myogen Begins Enrollment For Ambrisentan Phase III Studies

Esperion Gets $32.2M From Settlement With Stockholder

Keryx Acquiring Three Phase II Drugs In 'Success-Based' Buyout

With 'Hybrid' Business Model, Infinity Signs Amgen To Deal

ImmunoGen Moving Forward Alone With Cancer Products

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...